- Identification

- Properties

- Safety Data

- Specifications & Other Information

- Links

- Quick Inquiry

Identification

CAS Number

1187594-14-4

Name

Ilunocitinib

Synonyms

{1-(Cyclopropylsulfonyl)-3-pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidinyl}acetonitril {1-(Cyclopropylsulfonyl)-3-pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidinyl}acetonitrile {1-(Cyclopropylsulfonyl)-3-pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azétidinyl}acétonitrile 3-Azetidineacetonitrile, 1-(cyclopropylsulfonyl)-3-pyrimidin-4-yl)-1H-pyrazol-1-yl]- 1187594-14-4 2-pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrileIlunocitinib

SMILES

N#CCC1(CN(C1)S(=O)(=O)C1CC1)N1C=C(C=N1)C1N=CN=C2NC=CC=12

StdInChI

InChI=1S/C17H17N7O2S/c18-5-4-17(9-23(10-17)27(25,26)13-1-2-13)24-8-12(7-22-24)15-14-3-6-19-16(14)21-11-20-15/h3,6-8,11,13H,1-2,4,9-10H2,(H,19,20,21)

StdInChIKey

RVOUEXFKIYNODQ-UHFFFAOYSA-N

Molecular Formula

C17H17N7O2S

Molecular Weight

383.428

Properties

Appearance

White powder

Safety Data

Symbol

Signal Word

Warning

RIDADR 

NONH for all modes of transport

WGK Germany

3

MSDS Download

Specifications and Other Information of Our Ilunocitinib CAS 1187594-14-4

Identification Methods

Shelf Life

1 year

Storage

Store at 2~8°C, away from light.

Known Application

Ilunocitinib is a safe, effective, and convenient Janus kinase (JAK) inhibitor specifically designed to manage pruritus (itchiness) associated with allergic dermatitis, as well as to control atopic dermatitis (AD) in dogs aged 12 months and older. As a JAK inhibitor, Ilunocitinib works by interfering with the JAK-STAT signaling pathway, which is critical in mediating inflammation and immune responses in conditions like allergic and atopic dermatitis. By inhibiting this pathway, Ilunocitinib helps to reduce inflammation and alleviate the intense itching that often accompanies these conditions.

Atopic dermatitis in dogs is a chronic skin disease that can cause severe discomfort due to persistent itching and inflammation, leading to skin lesions, infections, and a decreased quality of life. Traditional treatments, such as corticosteroids, often come with long-term side effects, making the development of targeted therapies like Ilunocitinib a significant advancement in veterinary medicine.

Ilunocitinib offers a more targeted approach to managing the disease by directly inhibiting the pathways involved in the inflammatory response without broadly suppressing the immune system. Its safety profile and ease of administration make it a practical option for long-term management, improving the well-being of affected dogs and offering relief from the burdens of chronic dermatitis.

General View of Documents

HNMR of Ilunocitinib CAS 1187594-14-4

Links

This product is developed by our R&D company Caming Pharmaceutical Limited (http://www.caming.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly. https://www.watson-int.com/ilunocitinib-cas-1187594-14-4/